Europe
Specifically, the new approval was for adults with dMMR recurrent or advanced solid tumors who have progressed on or after previous treatment and who have no satisfactory alternatives.
Scientists from The Christie NHS Foundation Trust have begun human trials on the use of aspirin and avelumab in treating patients diagnosed with triple-negative breast cancer.
XVR011 is being observed in a randomized, double-blind, single-center, and placebo-controlled study to evaluate its pharmacokinetic activity and safety profile.
CureVac has revealed in its latest financial report that its lung cancer program with German biotechnology company Boehringer Ingelheim has been terminated.
Two experimental cancer drugs, one for ovarian cancer and one for a form of breast cancer, received Fast Track designation from the U.S. FDA, which will speed up the regulatory process for these medications.
There was plenty of clinical trial updates last week. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
On Monday, BioNTech announced revenues of €5.308 billion (about $6.2 billion) for the quarter.
AbbVie has terminated its license and collaboration deal with Molecular Partners for abicipar pegol, and returned all rights to the Swiss company. Here’s more about it.
Although August is a fairly busy month for PDUFA dates, there were only two on the U.S. FDA’s calendar for this week, and one of those has already been reported. Here’s a look.
PRESS RELEASES